Information 2020 Life Science Intellectual Property Forum How to protect new businesses that use digital data as a source of value - Multifaceted protection through IP and contracts
The "2020 Life Science IP Forum" will be held on Friday, February 14, 2020 at 1:00 p.m. at Ochanomizu Sola City Conference Center (Chiyoda-ku, Tokyo).
In the context of Society 5.0, which calls for new value creation in the fields of medical care, nursing care, and social life, the 2018 Life Science IP Forum will focus on the "Life Science Revolution brought by AI/Big Data" and discuss the current status and prospects of AI/Big Data utilization in the medical field and drug discovery, as well as IP strategies in the age of data, The forum was well received by the audience.
In light of the importance of the vast amount of data obtained in R&D these days, the Ministry of Economy, Trade and Industry (METI) has formulated the "Operational Guidelines for Data Management in Contract R&D" to create an environment that promotes the sharing and utilization of research data from projects involving the government, and from 2018, it will be implemented by the National Institute for Medical Research and Development (AMED), the Japan The Guidelines have been in operation at the National Institute for Research Advancement (AMED), the New Energy and Industrial Technology Development Organization (NEDO), and other organizations. In addition, insurance coverage for "gene panel testing" has been approved starting in 2019, with the aim of realizing cancer genome medicine. However, registration with the Cancer Genome Information Management Center (C-CAT) of the genetic information obtained through this testing process and the clinical information of the patient is a condition for the test, and it is expected that the aggregated data will contribute to medical care through its utilization. As described above, data management is required to be further improved in the life science field.
At the same time, it is becoming possible to provide a variety of user support services, such as medical treatment applications, specific medical checkup support applications, lifestyle improvement support applications, and home medical care support applications, by monitoring the status of patients and application users in real time, and there is a growing movement toward commercialization of these services.
In these new business models, multiple companies mutually provide software, devices, and medical-related services, and data is constantly distributed, accumulated, and utilized between them and users. Therefore, unlike the conventional model of protecting business by patenting the active ingredients of pharmaceuticals, which was the mainstream model in the pharmaceutical industry, multifaceted protection is said to be necessary through various intellectual property rights such as trade secrets under the Unfair Competition Prevention Law, patents, designs, trademarks, and copyrights, as well as contracts.
In light of this situation, this forum will introduce specific examples of recent new businesses of companies utilizing digital data, and discuss how to protect and handle the raw data of measurement results provided by users in such business models, as well as how secondary use of data and the protection and handling of results obtained as a result of such use should be handled. In addition to the protection and handling of the raw data of measurement results provided by users in such business models, we will discuss the secondary use of data and the protection and handling of results obtained as a result of the use. We invite representatives from industry, government, and academia to discuss these issues from an industrial policy perspective, transcending boundaries.
